These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 37515187)

  • 1. SARS-CoV-2 Spike Protein Is Capable of Inducing Cell-Cell Fusions Independent from Its Receptor ACE2 and This Activity Can Be Impaired by Furin Inhibitors or a Subset of Monoclonal Antibodies.
    Reuter N; Chen X; Kropff B; Peter AS; Britt WJ; Mach M; Überla K; Thomas M
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
    Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
    J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation.
    Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquisition of Furin Cleavage Site and Further SARS-CoV-2 Evolution Change the Mechanisms of Viral Entry, Infection Spread, and Cell Signaling.
    Frolova EI; Palchevska O; Lukash T; Dominguez F; Britt W; Frolov I
    J Virol; 2022 Aug; 96(15):e0075322. PubMed ID: 35876526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 Spike Furin Cleavage Site and S2' Basic Residues Modulate the Entry Process in a Host Cell-Dependent Manner.
    Lavie M; Dubuisson J; Belouzard S
    J Virol; 2022 Jul; 96(13):e0047422. PubMed ID: 35678602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle.
    Mondal T; Shivange G; Habieb A; Tushir-Singh J
    Microbiol Spectr; 2022 Feb; 10(1):e0236421. PubMed ID: 35138160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly Efficient SARS-CoV-2 Infection of Human Cardiomyocytes: Spike Protein-Mediated Cell Fusion and Its Inhibition.
    Navaratnarajah CK; Pease DR; Halfmann PJ; Taye B; Barkhymer A; Howell KG; Charlesworth JE; Christensen TA; Kawaoka Y; Cattaneo R; Schneider JW;
    J Virol; 2021 Nov; 95(24):e0136821. PubMed ID: 34613786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural and Recombinant SARS-CoV-2 Isolates Rapidly Evolve
    Shiliaev N; Lukash T; Palchevska O; Crossman DK; Green TJ; Crowley MR; Frolova EI; Frolov I
    J Virol; 2021 Oct; 95(21):e0135721. PubMed ID: 34406867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity.
    Neerukonda SN; Vassell R; Lusvarghi S; Wang R; Echegaray F; Bentley L; Eakin AE; Erlandson KJ; Katzelnick LC; Weiss CD; Wang W
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: Effects on proteolytic cleavage and ACE2 binding.
    Spelios MG; Capanelli JM; Li AW
    Immunol Lett; 2022 Feb; 242():1-7. PubMed ID: 35007661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis of severe acute respiratory syndrome coronavirus 2 infection.
    Ge J; Zhang S; Zhang L; Wang X
    Curr Opin HIV AIDS; 2021 Jan; 16(1):74-81. PubMed ID: 33186231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, evaluation, and mechanism of 1-(4-(arylethylenylcarbonyl)phenyl)-4-carboxy-2-pyrrolidinones as potent reversible SARS-CoV-2 entry inhibitors.
    Palla SR; Li CW; Chao TL; Lo HV; Liu JJ; Pan MY; Chiu YT; Lin WC; Hu CW; Yang CM; Chen YY; Fang JT; Lin SW; Lin YT; Lin HC; Kuo CJ; Wang LH; Chang SY; Liang PH
    Antiviral Res; 2023 Nov; 219():105735. PubMed ID: 37858764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides.
    Llewellyn GN; Chen HY; Rogers GL; Huang X; Sell PJ; Henley JE; Cannon PM
    J Virol; 2023 Aug; 97(8):e0068423. PubMed ID: 37555663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and functional modelling of SARS-CoV-2 entry in animal models.
    Brooke GN; Prischi F
    Sci Rep; 2020 Sep; 10(1):15917. PubMed ID: 32985513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Suitable Membrane Distance Regulated by the RBD_ACE2 Interaction is Critical for SARS-CoV-2 Spike-Mediated Viral Invasion.
    Wu M; Li W; Lin S; Fan J; Cui L; Xiang Y; Li K; Tang L; Duan Y; Chen Z; Yang F; Shui W; Lu G; Lai Y
    Adv Sci (Weinh); 2023 Oct; 10(28):e2301478. PubMed ID: 37590389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy.
    Ridgway H; Chasapis CT; Kelaidonis K; Ligielli I; Moore GJ; Gadanec LK; Zulli A; Apostolopoulos V; Mavromoustakos T; Matsoukas JM
    Viruses; 2022 May; 14(5):. PubMed ID: 35632769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACE2-Independent Interaction of SARS-CoV-2 Spike Protein with Human Epithelial Cells Is Inhibited by Unfractionated Heparin.
    Partridge LJ; Urwin L; Nicklin MJH; James DC; Green LR; Monk PN
    Cells; 2021 Jun; 10(6):. PubMed ID: 34200372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.